MELTF and clear cell renal carcinoma: Besides, MELTF-AS1 has also been reported as a biomarker for the treatment of osteosarcoma and renal clear cell carcinoma [29], and is associated with the prognosis of NSCLC, so this study selected MELTF-AS1 as the research object for follow-up experiments.